LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Monopar Therapeutics Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERMNPR
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / MNPR COVERAGE

What’s moving Monopar Therapeutics Inc. now

Current reporting with the operating signal separated from the noise.

01
Monopar Therapeutics Inc.: Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease

Monopar Therapeutics Inc.: Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease

The story matters when it changes Monopar Therapeutics Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Monopar Therapeutics Inc (MNPR) Receives a Buy from Piper Sandler

Monopar Therapeutics Inc (MNPR) Receives a Buy from Piper Sandler

The story matters when it changes Monopar Therapeutics Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Monopar Therapeutics Inc.: Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics Inc.: Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

The story matters when it changes Monopar Therapeutics Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025

Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025

The story matters when it changes Monopar Therapeutics Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Monopar Therapeutics Inc. Announces $40 Million Underwritten Offering of Common Stock and Private Placement

Monopar Therapeutics Inc. Announces $40 Million Underwritten Offering of Common Stock and Private Placement

Investors are testing whether Monopar Therapeutics Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
06
Monopar Therapeutics Inc: A Promising Buy Amid Progress in Oncology Programs and Stable Financial Situation

Monopar Therapeutics Inc: A Promising Buy Amid Progress in Oncology Programs and Stable Financial Situation

The story matters when it changes Monopar Therapeutics Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
07
Monopar Therapeutics Inc. (MNPR) Could Find Support Soon, Here's Why You Should Buy the Stock Now

Monopar Therapeutics Inc. (MNPR) Could Find Support Soon, Here's Why You Should Buy the Stock Now

Investors are testing whether Monopar Therapeutics Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest MNPR filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-14 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-13 · Period 2025-09-30SEC ↗10-K/AAnnual financial reportFiled 2026-04-01 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-22 · Period 2026-07-22SEC ↗8-KMaterial company eventFiled 2026-06-30 · Period 2026-06-30SEC ↗8-KMaterial company eventFiled 2026-06-26 · Period 2026-06-26SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-30 · Period 2026-06-22SEC ↗S-8 POSOfficial SEC filingFiled 2026-07-22SEC ↗
EARNINGS / QUARTERLY TRACKER

Monopar Therapeutics Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.